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a  b  s  t  r  a  c  t
Objectives: To review the available data about stereotactic body-radiotherapy (SBRT) for
oligometastatic lymph node cancer recurrence.
Methods: The inclusion criteria for this study were as follows: Medline search for the (1)
English language (2) full paper (abstracts were excluded) on (3) adult oligometastatic solid
cancer recurrence limited to lymph node that underwent SBRT (4) outcome data available
and (5) published up to the 30th April 2014.
Results: 38 papers fulfilling the inclusion criteria have been found: 7 review articles and
31  patient series (20 and 11 retrospective and prospective studies, respectively) including
between 1 and 69 patients (636 lymph nodes). Twelve articles reported only lymph node
SBRT  while in 19 – all types of SBRT including lymph node SBRT were presented. Two-year
local  control, 4-year progression free survival and overall survival was of up to 100%, 30% and
50%, respectively. The progression was mainly out-field (10–30% of patients had a recurrence
in  another lymph node/nodes). The toxicity was low with mainly mild acute events and
single grade 3–4 late events. When compared to SBRT for any oligometastatic cancer, SBRT
for  lymph node recurrence carried better prognosis and showed lower toxicity.
Conclusions: SBRT is a feasible approach for oligometastatic lymph node recurrence, offering
excellent in-field tumor control with low toxicity profile. The potential abscopal effect hasbeen  hypothesized as a basis of these findings. Future studies are warranted to identify
the  patients that benefit most from this treatment. The optimal combination with systemic
treatment should also be defined.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.∗ Corresponding author at: Department of Radiotherapy, European Insti
Tel.:  +39 0257489037; fax: +39 0294379227.
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reports of practical oncology and 
.  Introduction
ligometastatic cancer recurrence is a recently established
istinct clinical entity.1,2 Indeed, local cancer treatment like
urgical metastasectomy has been used in selected patients
nd histology types (sarcoma, breast cancer, colorectal cancer
tc.) allowing for long term disease control in a good pro-
ortion of cases.3–5 These findings confirm distinct biology
f oligometastases based on the restricted tumor metastatic
apacity.2 In the last decade stereotactic body radiotherapy
SBRT) has become a new local treatment option for the
imited volume primary cancer (non small cell lung can-
er, hepatocellular carcinoma, renal cancer, prostate cancer
tc.) or oligometastases.6,7 As a non-invasive (or minimally
nvasive if fiducial positioning is required) short out-patient
rocedure it has been immediately introduced in the vari-
us scenarios of cancer patients for the treatment of primary
r secondary lesions. Moreover, several benign conditions as
rterio-venous malformations, epilepsy, trigeminal neuralgia
r benign tumors including meningioma, vestibular schwan-
oma, pituitary tumors, are being treated successfully with
tereotactic irradiation. Medline search using terms “stereo-
actic radiotherapy” showed 13,020 articles, out of which 8385
64%) and 5136 (40%) have been published in the last 10 and
 years, respectively. When “radiosurgery” (single fraction
tereotactic radiotherapy) was used for Medline search, 11,215
rticles were found, 7238 (65%) and 4405 (40%) published in the
ast 10 and 5 years, respectively.
Recurrent lymph node cancer after the primary treatment
s considered a sign of disease dissemination and as such is
arely approached with local treatment like surgery or limited-
eld radiotherapy. Systemic therapy like chemotherapy,
ndocrine treatment or new biological agents are considered
he golden standard in patients with lymph node recurrent
ancer. At that time the cancer is rarely symptomatic, so the
ain symptoms reported by the patient will be treatment
ide effects lowering the quality of life and requiring hospital
ccess. Therefore, local therapy if safe and effective is eas-
ly accepted by the patient. Recently published data suggest
hat SBRT might offer good local control in selected patients,
lthough the majority of reports are retrospective and include
mall patients series with heterogeneous tumor sites.
The aim of our study was to evaluate the available lit-
rature on the SBRT as a therapeutic approach to lymph
ode recurrent cancer. SBRT is a novel radiotherapy modality,
hat takes advantage of the recently available image  guid-
nce technologies and radiation dose delivery techniques
o administer ablative doses selectively to the target lesion,
eading to acceptable toxicity with respect to conventional
echniques. The available literature has been reviewed in
rder to evaluate the efficacy and toxicity profile of this
nnovative treatment in lymph node recurrent cancer.
.  Material  and  methods.1.  Study  protocol
his is a review study on the SBRT for recurrent
ligometastatic solid cancer limited to lymph nodes.therapy 2 0 ( 2 0 1 5 ) 472–483 473
2.2.  Inclusion  criteria
The inclusion criteria for this study were as follows: Medline
search for the (1) English language (2) full paper (abstract were
excluded) on (3) adult oligometastatic solid cancer recurrence
limited to lymph node that underwent SBRT (4) outcome data
available and (5) published up to the 30th April 2014.
The following Medline terms were used: stereotactic radio-
therapy, stereotactic radiosurgery, lymph node, lymph node
recurrence. The articles were checked for the availability of
the information relative to SBRT outcome in terms of effi-
cacy and/or toxicity profile. The articles dedicated exclusively
to other aspects of SBRT (diagnostic, dosimetric or techni-
cal issues, incidental lymph nodal dose from SBRT etc.) were
excluded.
2.3.  Review  and  analysis  of  the  available  literature
The articles were reviewed in their full version by two  authors
(SR, BAJF). The papers were categorized as (1) review arti-
cles and (2) articles that included outcome information of the
patient series.
3.  Results
Thirty eight papers fulfilling the inclusion criteria have been
found: 7 review papers5,7–12 and 31 patient series reporting
treatment (636 lymph nodes treated with SBRT).13–43
Out of 7 review articles, only 1 is dedicated exclusively to
the lymph node SBRT,8 and 2 describe treatment options for
lymph node recurrence including SBRT.11,12
Thirty one clinical series reporting treatment outcome (in
the series of 1–69 cases of lymph node recurrence) were
divided in those including patients treated with SBRT only for
lymph node recurrent cancer (12 articles)32–43 and those on
the patients treated for any oligometastatic cancer to any sites
including lymph nodes (19 articles).13–31 The first article of this
series was published in 2005.23 Twenty eight out of 31 articles
(90%) have been published in the last 6 years (2008–2013).
Most probably some patients have been included in more
than one article (along with updated follow-up) and whenever
this information was clear in the text, it is also specified in the
present review and tables.13–15,28–31,38,42,43
3.1.  Clinical  series  reporting  SBRT  outcome
3.1.1.  Series  including  SBRT  for  lymph  node  recurrence
only
Twelve out of 31 clinical series reporting outcome included
patients treated with SBRT for lymph node recurrence
only32–43 (Table 1). All but 2 series were retrospective.
3.1.1.1.  Case  profile  and  tumor  sites.  Altogether 290 patients
(350 lymph nodes) were included in 12 articles. The majority
(7 articles) included patients treated exclusively for abdomino-
pelvic lymph nodes.32–36,38,43 Three articles included patients
treated exclusively for paraaortic lymph node.40–42 Cervical
lymph node and miscellaneous sites (mediastinum, abdomen









































Nature of study SBRT technique Primary
site/histology











Previous CHT in 12/32
treatments (37.5%)
Yes  for pelvic targets
with CBK
LN  size < 2 cm: 11
(34.4%), 2–2.99 cm: 11
(34.4%), > 3 cm: 10
(31.2%)
Alongi et al., 201233 25 pts, 28
abdomino-pelvic LN
Retrospective VMAT RapidArc using
FFF beams
Miscellaneous Previous CHT in 20/25 pts Not reported Mean CTV volume
17.4 cm3







Previous CHT in 25/33 pts
(70%)
Not reported Not reported
Jereczek-Fossa
et al., 201235 a
69 pts, 94
abdomino-pelvic LN





Concomitant CHT in 9
cases, HT in 23 cases, both
in 3 cases




19 pts with abdominal
LN
Retrospective 3D-CRT and VMAT
RapidArc




25 pts with limited
nodal recurrence
Prospective LINAC, IMRT multiple
coplanar and
non-coplanar arcs
Prostate cancer No Not reported Not reported
Jereczek-Fossa
et al., 200938
14 pts; 16 LN Retrospective LINAC and CBK Prostate cancer Concomitant ADT in 7 pts,
docetaxel + LHRH in 1 pt
Yes in 7 pts treated
with CBK
Not reported
Kim et al., 201039 9 pts, 29 cervical LN Retrospective CBK Nonanaplastic
thyroid cancer
Previous radio iodine in 8
pts
Not  reported Total cumulative LN
volume: range
1.6–43.6 ml
Kim et al., 200940 7 pts treated for
paraortic LN
Prospective CBK Gastric Adj CHT after gastric
resection in 4/7 pts, 5-FU
before SBRT in all pts
Yes CTV median volume
21 ml





CHT  in 25 pts: 2 pre-, 9
concomitant, 14 post-SBRT
Yes  PTV volume range
1.3–57.3 cm3
Kim et al., 200942 b 7 pts, 11 para-aortic LN Retrospective CBK Colorectal CT before SBRT for all pts,
all non-responders
Yes GTV median volume
22 ml
Kim et al., 200843 b 23 pts treated for
isolated pelvic LN
Retrospective CBK Rectal cancer Salvage-CHT before SBRT
for all pts








Toxicity Overall survival Local control/pattern of failure





No  severe acute or late
toxicity
All  pts alive at last
follow-up
Freedom of local PD: 100%. LC 90.9% in pts with
prostate histology. Distant PD in 8 pts (25%)
Alongi et al., 201233 No 45 Gy in 6 fr (7.5 Gy/fr) 195
days
Acute: G1–G2 in 4 pts; no
≥G3. Late: none.
Not  reported Overall response rate 82% (at median follow-up)
Corvò et al., 201334 Yes in 3/33 pts (8%):
median dose of
previous RT 30 Gy
Median 35 Gy in 5 fr
(7 Gy/fr) 1 fr/week
28
mo
Acute:  G1–G2 in 24 pts, no
≥G3. Late: none
55%  at median
follow-up
LC in 30 pts (83%); 16 pts died at median











































Toxicity Overall survival Local control/pattern of failure
Jereczek-Fossa et al.,
201235  a
Yes for 20 lesions
(21%). For 8 pts
(9%) SBRT as boost








3-year OS: 49.9%, 3-year LC: 64.3%
2-year PFS: 20% (dominant pattern of failure:
out-field)




Acute: G1 in 1 pt, no ≥G2.
Late: G1 in 1 pt, G3 in 1 pt
2-year OS: 93.3% LC at 24 mo: 77.8%
2-year PFS 19.7%
Patterns of failure: 2 pts local + distant; 2 pts only
regional 7 pts distant PD
Casamassima et al.,
201137
Not reported SBRT 30 Gy in 3 fr,
(10 Gy/fr) in 18 pts; 24 Gy
boost in 3 fr in 7 pts
29
mo
No ≥G1 events 3-year OS: 92% Progression in 10 pts:
- 2 pts bone






No Mean 30 Gy/3 fr (10 Gy/fr) 18.6
mo
Acute: none. Late: only G2
in 1 pt
8  NED, 4 AWD, 1 alive
with biochemical
failure, 1 died for
other cause
No local recurrences; clinical PD in 5 pts after
mean 12.7 mo
No in-field PD
Distant PD in 2 pts
Regional PD in 3 pts




No  ≥G3 toxicity Not reported 5-year local PFS: 100%
Regional failure in 4 pts (2 of them salvaged by
additional SBRT)
Distant PD in 4 pts




Acute: G1 in 2 pts. Late:
none
3-year OS: 43% Local relapse in 1 pt (at 23 mo)
Distant failure in 5 pts
3 year PFS: 29%
Choi et al., 200941 SBRT as boost in 4
pts
33–45 Gy in 3 fr





Acute: ≥G3 in 5/30 pts
during CHT





4  year LC: 67.4%
4 year PFS: 45%
Relapse in 11 pts: locoregional alone 4 (13.8%),
distant alone 3 (10.3%), locoregional + distant 2
(6.9%), recurrence at vaginal stump in 2 pts
Kim et al., 200942 b No Median 48 Gy (range
36–51 Gy) in 3 fr (16 Gy/fr)
26
mo
Acute: G1: 2/7 pts
G4: 1 pt
Late: none
3-year-OS 71.4%, Local recurrence in 1 pt at 13 mo. after SBRT;
regional recurrence in 1 pt; distant failure in 4
pts; 1 pt NED at 26 mo
Kim et al., 200843 b In 4 pts SBRT alone: median dose
39 Gy in 3 fr (13 Gy/fr);
SBRT as boost: 16 Gy in
single fr (NTD 65 Gy)
31
mo
Acute: G1–G2: 9 pts (39%)
G4 in 1 pt
None in the 4 reirradiated
pts Late: none
5-year OS 23.2% 4 year LC: 74.3%
PD in 45% (9/20) (2 local, 6 distant, 2 both).
4-year PFS 51.1%
Legend: Adj – adjuvant, ADT – androgen deprivation therapy, AWD – alive with disease, BED – biologically equivalent dose, CBK – CyberKnife, CHT – chemotherapy, CTV – clinical target volume, 3D-CRT
– 3 dimensional conformal radiotherapy, DFS – disease free survival, EBRT – external beam radiotherapy, FFF – flattening filter free, 5-FU – 5-fluorouracil, fr – fractions, G1-G2-G3-G4 – grade 1, 2, 3, 4,
GTV – gross tumor volume, IG-IMRT – image guided intensity modulated radiotherapy, IMRT – intensity modulated radiotherapy, LC –  local control, LHRH – luteinizing hormone releasing hormone
analogue, LN – lymph nodes, mo – months, mts – metastasis, NED – no evidence of disease, NTD – normalized total dose, OS – overall survival, PD – progressive disease, PFS – progression free survival,
pts – patients, PTV – planning target volume, RT – radiotherapy, SBRT – stereotactic body radiotherapy, VMAT – Volumetric modulated Arc Therapy.
a Included updated information about 7 prostate cancer pts analyzed in previous report (Jereczek-Fossa et al., 200938).
b Some patients are included in Kang et al. 201013 and Bae 201214.
d rad476  reports of practical oncology an
Primary cancer was limited to miscellaneous origin, gastro-
intestinal malignancies, prostate, gynecological and thyroid
cancer in 5, 3, 2, and 1, 1 articles, respectively (Table 1).
3.1.1.2.  Staging,  target  definition  and  concomitant  therapy.  In
the majority of the series staging was performed with use
of total body contrast medium computer tomography (CT)
and/or [18F]fluoro-deoxy-glucose (or [11C]choline in prostate
cancer) positron emission tomography/CT scan (PET/CT). In
only one series biopsy of target lesion was performed in a
subset of patients.35 In all cases patients received previous
therapies and in some proportion SBRT was proposed as re-
irradiation. Concomitant systemic treatment was allowed in
some series.35,38,41
3.1.1.3.  SBRT  technique  and  doses.  Various techniques were
used for SBRT, including CyberKnife (in 5 articles all patients
were treated with CyberKnife), Tomotherapy, RapidArc and
other linacs. Fiducials were positioned mainly for CyberKnife
treatment. Ablative doses were employed given in median 3
fractions (1–6 fractions) of 7–16 Gy each.
3.1.1.4.  Tumor  outcome.  In all series overall response rate was
excellent (up to 80%). Long term local control rate was very
high and in some cases was 100%. The dominant pattern of
failure was out-field: distant metastasis or regional lymph
nodes. Regional lymph node recurrence occurred in about 10%
of all patients and constituted about 50–80% of all events of
progressive disease.
Three-year progression free survival (progression at any
site) exceeded 20%36,40 and seemed to be longer in gastro-
intestinal tumors.40,43
Overall survival rates up to 93.3% at 2 years36 and 71.4% at
3 years37 were observed.
3.1.1.5.  Toxicity.  Both acute and late toxicity was limited.
Mainly mild (grade 1 or 2) acute events were observed
and in the majority of the series no late toxicity was
registered.32–34,37,40–43 Median follow-up of about 2–3 years in
all series might not allow for full toxicity evaluation.
3.1.2.  Series  reporting  SBRT  for  any  oligometastatic  site
including  lymph  nodes
Nineteen out of 31 clinical series reporting outcome included
patients treated with SBRT for any site including lymph node
recurrence13–31 (Table 2). Nine studies (29%) were prospective,
including 1 phase I trial.22
3.1.2.1.  Case  profile  and  tumor  sites.  Sixteen hundred lesions
were treated with SBRT in 19 series and 286 were lymph nodes
(18%). The treated sites included mainly abdomino-pelvic and
miscellaneous areas. Three studies reported on the head and
neck area only.20,21,25 In the majority of series miscellaneous
all primary cancer sites were treated and in some only gas-
trointestinal, genitourinary or head and neck malignancies
were included (Table 2).3.1.2.2.  Staging,  target  definition  and  concomitant  therapy.  In
the majority of the series staging was performed with use of
total body contrast medium CT, magnetic resonance imagingiotherapy 2 0 ( 2 0 1 5 ) 472–483
(MRI) and/or [18F]fluoro-deoxy-glucose (or [11C]choline in
prostate cancer) PET/CT scan. In only one series biopsy of
target lesion was performed in a subset of patients.15 In
all cases patients received previous therapies and in some
proportion SBRT was proposed as re-irradiation. Several
SBRT courses were proposed in some series.15–17,23,28–30 Con-
comitant systemic treatment was allowed in some series,15–18
especially if prostate cancer patients were included (androgen
deprivation).
3.1.2.3.  SBRT  technique  and  doses.  In 7 reports CyberKnife was
used for SBRT and in the remaining 12 – other linacs were
employed. Fiducials were positioned mainly for CyberKnife
treatment (in case of head and neck lesions – only for the
tumors positioned below the 4th cervical vertebra).21 Abla-
tive doses were employed given in median 3 fractions (1–10
fractions) of 5–24 Gy each. Generally speaking higher median
doses were employed in these reports when compared to the
series including lymph node SBRT only (the doses to the lymph
node and other lesions were not reported separately).
3.1.2.4.  Tumor  outcome.  Local control rates were high and
ranged from 61% to 67% at 1 year to 53–88%, 64–98%, 73–82%
and 57% at 2, 3, 4 and 5 years after SBRT. Dose escalation was
correlated with increase in local control.22
Progression was mainly out-field. Regional progression
was reported in up to 36% of patients (including all sites of
metastases).14 In case of prostate and colorectal malignancies,
recurrence limited to lymph nodes carried longer progression
free survival when compared to the other recurrent sites (pri-
mary  tumor or metastases).13,15
Overall survival rates were high and ranged from 80% at 1
year to 50–65%, 22–60% and 13–28% at 2, 3 and 5 years after
SBRT (Table 2). Shorter overall survival was observed in lymph
node recurrence from head and neck cancer when compared
to other recurrence sites of this malignancy.25
3.1.2.5.  Toxicity.  Both acute and late toxicity was somehow
higher than in the lymph node only series: acute toxicity was
up to 77% and single late G4–G5 events were reported. Severe
events included intestinal perforation or obstruction and were
observed at high doses (48–51 Gy).14 In particular, high toxicity
was observed in the re-irradiation cases.21
4.  Discussion
Our review showed that SBRT may be a safe and effective
approach to oligometastatic lymph node recurrence, offering
excellent in-field tumor control with low toxicity profile. The
main limitations of our review include retrospective nature of
the majority of the articles (65%), small number of patients
included in each series (ranging from 1 to 69 patients), het-
erogeneity of histotypes, SBRT approaches and doses and
recurrence site (lymph nodes versus all recurrence sites). To
the best of our knowledge, no comparative studies (like case-
control series etc.) have been published. The information on
the patient- and treatment-related variables and outcome
data (toxicity, tumor control) have been reported in incon-








































No. of LN treated/(the
whole series)
Nature of study SBRT technique Primary site/histology Systemic therapy Fiducial markers Treated volumes
Kang et al.,
201013  a
41 (78): pelvic (29 ln)
Para-aortic (11 ln, 7 pts)
Mediastinal (1 ln, 1 pt)
Retrospective CBK Colorectal cancer CHT before SBRT in 49/59
pts
Not reported Cumulative CTV median
volume for LN: 24 cm3
Bae et al.,
201214  b
19 (50); no. of pts treated
on LN: 18 (41)
Retrospective CBK Colorectal cancer Adj CHT in all pts; adj CHT
after SBRT in 33 pts; neoadj
CHT before SBRT in 21 pts
Not reported Cumulative GTV volume
for LN: median 18 cm3;
total cumulative GTV
volume: median 13 cm3
Jereczek-Fossa
et al., 201215 c
18 (38) total number of
pts: 34
Retrospective CBK Prostate cancer ADT in 18 pts/21 lesions
(12/18 LN mts lesions),
estramustine in 1 pt
Yes in 26 lesions











treatments (40%): CHT 32,
HT 3, both 12





22(49), (11/24 pts) Prospective (single
arm study)
LINAC Prostate cancer Yes: single short acting
LH-RH
analog + antiandrogen 1
month before SBRT
Not reported Not reported
Ahmed et al.,
201318
1/21 Prospective IMRT and 3D-CRT Prostate cancer In 15 pts (88%) ADT after
completion of SBRT
Not reported Not reported
Hoyer et al.,
200619
3 pts/64 pts (5%) Prospective phase II
trial
LINAC Colorectal cancer Neoadj CT before SBRT in
33/64 pts (52%)









No concomitant Not reported GTV median volume
11.6 cm3
Roh et al., 200921 11 (44): 8 neck LN and 3
retropharyngeal LN
Retrospective CBK Miscellaneous In 21 pts (58.3%) previous
CHT in 6 pts CHT after SBRT
Yes in pts with


















6 (162) Retrospective LINAC Renal cell carcinoma Prior systemic treatment in
15 pts













of head and neck)
CHT not allowed, only HT
allowed. Prior systemic
therapy in 49 pts (80.3%)




8 of the 22 pts had LN
mts (1 limited
recurrence with LN)
Prospective CBK Squamous cell
carcinoma of
head&neck
Low dose oral 5-FU from 1
mo after SBRT









































No. of LN treated/(the
whole series)







Not reported Not reported Not reported PTV volume in
abdominal lesions:





Retrospective VMAT RapidArc Miscellaneous
(mostly colorectal,
pancreatic)
No  Not reported Max axial diameter:





28 pts (121) (24 pts









No  Not reported Median sum of GTVs
28 cm3 mean 52 cm3
Milano et al.,
200829 d









Not  reported Not reported Thoracic LN: median
19 cm3 abdomino/pelvic








Retrospective Conformal arcs or
multiple fixed
coplanar beams
Miscellaneous Not reported Not reported GTV median volume
6 cm3, mean 4 cm3
Authors, year of
publication
Re-irradiation SBRT dose Median follow-up Toxicity Overall survival Local control/pattern of failure
Kang et al., 201013 a Not reported SBRT alone (26 pts):
36–51 Gy in 3 fr, NTD
66–115 Gy. SBRT as
boost (5 pts): 16 Gy in
single fr, NTD 35 Gy
(+40–45 Gy EBRT)
32 mo Pelvic LN: G1–G2: 9/23 pts;
G4: 1/23 ptsa
Para-aortic LN: G1–G2: 2/7
pts; G4: 1/7 ptsa
3-year OS 49% 3-year LC 66%
3 year PFS 25%
Failure pattern NED 21 pts
PD 35 pts (local 8, distant 11, regional 8)
Bae et al., 201214  b In 1 case, after
previous SBRT
For  LN mts: median
48 Gy, (45–51 Gy) in 3
fr
28 mo Acute G1–G2: 17 pts (39%)
Late ≥G3 in 3 pts (7%): liver,
pelvic LN, paraortic LNb
3-year and 5-year
OS: 60% and 38%
3-year and 5-year LC: 64% and 57%
PD in 23/41 pts (56%): 14 local, 15 regional,




(71%), of which 8 LN
mts (8/18)
Median 30 Gy in 4.5
fr (for LNs: 33 Gy/3 fr)
16.9 mo None in 68% of pts. Acute: 1
G3
LN SBRT (1/16 = 6%)
Late G3: 2 (6%)
At  the time of
analysis: 19 pts NED,
15 pts AWD
PFS at 12 mo 68.1% at 18 and 30 mo. 42.6%
(63.5% in LN group)
PFS longer in case of LN recurrence
(median PFS > 30 mo) than for other sites
(11–14 mo)




Yes in 47/118 total
lesions (40%)












































Table 2 – (Continued)
Authors, year
of publication
Re-irradiation SBRT dose Median follow-up Toxicity Overall survival Local control/pattern of failure
Berkovic et al.,
201317
Not reported Median 50 Gy in 10 fr
BED:
80 (if ˛/ˇ = 3); 92 (if
˛/ˇ = 1.5)




12  pts AWD at last FU,
1-year
ADT-FS 82%, 54% at 2
years; median
deferment of ADT: 38
mo
LC  100%, no in-field PD
Pattern of recurrence: 11 pts
oligometastatic, 6 pts multiple




Not reported Dose to LN: 50 Gy in
5 fr
For  LN: 4.4 mo Acute: G1–G2: 3 cases (for
LN no acute toxicity)
No late toxicity
12  mo CSS 100% 2 pts died for distant PD at last FU
12 months FFDP 40%
Hoyer et al.,
200619
Yes in 1 pt 45 Gy in 3 fr 4.3 years, 1 pt
lost to FU
(within 6 mo): G4: 1 pt
G3: 3 pts
3-year and 5-year OS:
22% and 13%
2 year LC: 79%
Local failure in 10/141 lesions
progression pattern: 1 pt only




Yes in 21/34 pts
(65%). Median dose
of previous RT 60 Gy,
median interval 51
mo
Median 30 Gy in 5 fr 16 mo Acute: none




median survival 28 mo
Overall response rate 61.9%





Median 30 Gy in 3–5
fr





Acute in 24 pts (G1-G3)
Late in 3 pts 8.6%
1 treatment-related death
(33 Gy in 3 fr to
retropharyngeal LN)
1-year OS and 2-year
OS 52.1% and 30.9%
1-year and 2-year LC: 61% and
52.2%
Pattern of failure: local in 17 pts (in
field 14.5%, out field 8.6%,
marginal 5.7%), regional 2 pts
(5.7%), distant 3 pts (8.6%)
Greco et al.,
201122
No Median 24 Gy in
single fr (starting
from 18 to 20 Gy,
than from 2006
22–24 Gy)
18  mo, no pts
lost to FU
Acute  G3 in 2 cases
Late ≥G3 in 11/103 pts,
overall incidence of G3 late
tox < 4%
Not  reported 2 year LC 64%
29 local failures
2 year LC 82% for high doses
(23–24 Gy), 25% for low doses
(18–20 Gy), 69% for intermediate




Not reported Most frequent:
10 Gy × 3–4 (2–5 fr,
with
5–16 Gy/fraction)






50% G1–G2; G4 in 1 pt
Median survival time:
19- > 58 mo
LC rate: 98%
Distant failure in 73%
Salama et al.,
201224
Not allowed Starting dose: 24 Gy
(8 Gy × 3); dose
ceiling was 60 Gy
(20 Gy × 3) for all
cohorts
20.9 months Acute: G3: 2
Late: G3: 6 (1 GI bleeding




1-year and 2-year LC: 67.2% and
52.7%; 1 year, 2 year PFS: 33.3%,
22%
Patterns of failure: In 7 pts (11.7%)
in field PD as first progression 33




































Table 2 – (Continued.)
Authors, year of
publication
Re-irradiation SBRT dose Median follow-up Toxicity Overall survival Local control/pattern of failure
Kawaguchi et al.,
201025
Yes in 14 pts;
previous RT dose





(range 20–42 Gy) in
2–5 fractions
24  mo Acute: G2: 17 pts (77.3%)
G3: 5 pts (all in re-RT)
Late: G1: 11 ptsG2: 3 pts
2  year OS in pts
without LN mts
78.6% vs 12.5% in pts
with LN mts
CR maintained at a median 2-years
follow-up in 10/22 pts (45.5%)
Scorsetti et al.,
201126
Not reported 45 Gy in 6 fractions Minimum follow-up
3 mo
Acute  tox: 2 G2 in abdomen Not reported Early LC in 89%
Outcome at 1st evaluation (55 pts
evaluable of 70):
CR 10, PR 26, SD 13, PD 6
Scorsetti et al.,
201127
Not reported 45 in 6 daily
fractions (7.5 Gy/fr)
for LN mts
12 mo Acute: G1 in 5 pts
Late: G3 in 1 pt
G1 in 1 pt
Not reported 6-mo crude LC rate: 79.2%
Milano et al., 200828 In 6 pts Preferred schedule
50 Gy in
5 Gy-fractions over 2
weeks
41  mo G1 in 1 pt
G2 in 3 pts
2-year and 4-year
OS: 50% and 28%
2-year and 4-year LC: 77% and 73%
2-year and 4-year PFS: 26% and 20%
15/121 pts only local failure




received SBRT as a
boost after
mediastinal RT









2-year and 4-year LC: 77% and 73%
Local failure in 57/293 lesions











No  ≥ G2 toxicity in the 9
pts reirradiated for a
locally recurrent lesion
2-year and 4-year
OS: 65% and 33%
2-year and 4-year LC: 88% and 82%
2-year and 4-year PFS: 54% and 28%
18/155 lesions failed locally
19/32 pts developed DM not amenable to
curative-intent treatment
Legend: Adj – adjuvant, ADT – androgen deprivation therapy, ADT-FS – androgen deprivation therapy free survival, AWD –  alive with disease, BED – biologically equivalent dose, CBK – CyberKnife,
CHT – chemotherapy, CR – complete response, CSS – cancer specific survival, CTV – clinical target volume, 3D-CRT – 3 dimensional conformal radiotherapy, DFS – disease free survival, DM – distant
metastases, EBRT – external beam radiotherapy, FFF – flattening filter free, fr. – fractions, 5-FU – 5-fluorouracil, G1–G2–G3–G4 – grades 1, 2, 3, 4, GTV – gross tumor volume, HT – hormonal therapy,
IG-IMRT – image guided intensity modulated radiotherapy, IGRT – image guided radiotherapy, IMRT – intensity modulated radiotherapy, LC –  local control, LHRH – luteinizing hormone releasing
hormone analogue, LN – lymph node, mo – months, mts – metastasis, NED – no evidence of disease, Neoadjuv – neoadjuvant, NTD – normalized total dose, OS – overall survival, PD – progressive
disease, PFS – progression free survival, PR – partial response, pts – patients, PTV – planning target volume, RT – radiotherapy, SBRT – stereotactic body radiotherapy, SD – stable disease, tox – toxicity,
VMAT – Volumetric modulated Arc Therapy.
a It includes some patients considered in Kim et al., 200942 (the patient with G4 toxicity treated on para-aortic node is the same) and Kim et al. 200843 (the patient with G4 toxicity treated on pelvic
node is the same).
b It includes some patients considered in Kim et al., 200942 (the patient with G4 toxicity treated on paraortic node is the same), Kim et al., 200843 (the patient with G4 toxicity treated on pelvic node
is the same), it evaluates the results of high doses > 45 Gy (escalation up to 60 Gy for liver and lung metastases, not for lymph nodes due to G4 toxicity at 48 and 51 Gy).
c 7 pts with lymph node recurrence included in the preliminary report, Jereczek-Fossa et al., 2009,38 have included in this series with updated follow-up.
d Descriptive analysis of the 121 pts considered in the previous prospective study Milano et al., 2008.28
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escriptive analysis. The impact of dose (physical or nor-
alized) and fractionation on tumor control remains to be
stablished.22,29 The effect of tumor volume on the local con-
rol has been observed in some studies,29 but clear conclusion
annot be drawn at present. Despite these constraints, we
o believe that our review adds new insight to the current
nowledge on cancer recurrence and its therapeutic options.
blative dose SBRT has revealed as an high-precision, non-
nvasive, short, well tolerated and convenient approach in the
atients that otherwise would be offered long lasting systemic
alliative treatment like chemotherapy, androgen depriva-
ion etc. Progress in cancer imaging (early diagnosis of small
olume primary or metastatic tumors) and the development
f high precision radiotherapy will probably lead to further
ntensification of local treatment, increasing its role in cancer
anagement.44–46
According to our review, cure may be obtained in a small
ut constant patient percentage (20–30% at 2 years) and in
any long treatment-free interval can be observed.17 This
ast endpoint has been only recently introduced in the cancer
esearch methodology and reflects the importance of qual-
ty of life issues, cost-effectiveness evaluation and last but
ot least, possibility of making cancer a chronic condition.47
ndeed, a new paradigm of the “chronic curable cancer” has
een recently proposed.47
Lymph node only recurrence constitutes a particular clin-
cal situation. A patient is usually asymptomatic and burden
f the disease is extremely low. Surgery for lymph node recur-
ent tumor might be challenging, and is limited by the previous
herapies that could lead to the high morbidity and the risk of
acro- or microscopic residual disease. Extended field exter-
al beam radiotherapy can also carry a risk of normal tissue
njury especially if the treated volumes are overlapping with
he previous surgical or radiotherapy area and high doses
re used. SBRT with extremely limited normal tissue irradia-
ion may overcome these difficulties. As shown in our review,
cute toxicity was low and only single severe late events
ere reported, limited to the cases of high SBRT dose to the
ear visceral organs (mainly bowel). These findings are eas-
ly explained by both intrinsic features of SBRT (i.e. extremely
igh precision in dose delivery) and typically small volume
f lymph node recurrence. In fact, the toxicity was somehow
igher in the series reporting SBRT for any tumor site includ-
ng lymph node where the toxicity was not reported separately
or lymph nodes and other sites. Non-lymph node recurrences
ave usually bigger volumes leading to higher toxicity rates in
he mixed series when compared to the lymph node series
nly.
Regional progression (disease occurrence in other, non irra-
iated lymph node) is greatly feared when SBRT is employed.
ndeed, some authors suggest elective conventional radiothe-
apy to the lymph node region combined with SBRT boost
o the positive lymph node.12 Based on the current review,
etween 10% and 30% of the patients treated with SBRT for
ingle lymph node recurrence will recur in other lymph node
nd in these cases further SBRT is often feasible.17,35 The risk
actors for regional progression cannot be defined due to the
mall number of cases in each series. However, higher risk
f regional progression (30%) was reported in all-sites series
hen compared to the isolated lymph node recurrence onlytherapy 2 0 ( 2 0 1 5 ) 472–483 481
(10%). This finding suggests that more  advanced cases were
included in the former series. Distant metastases, primary
recurrent, visceral metastases etc. are well known to have
worse prognosis when compared to the isolated lymph node
recurrence.
The mechanism of effect of SBRT on the cancer lesions is
not yet clear. Apart from the direct effect of SBRT on clonogenic
cancer cells, an abscopal effect (a regression of non-irradiated
lesions distant from the irradiated tumor site) was also
hypothesized.6 This out-of-field systemic phenomenon has
been observed in numerous malignancies (renal cancer,
melanoma, lung cancer), however, its mechanisms are not
yet well understood and include several post-radiation anti-
tumor immune processes and inflammatory reactions.48–50
Reduction of cancer cell seeding was also suggested.5 These
effects might be enhanced when targeted drugs and SBRT
body radiotherapy are combined.48–50
In conclusion, our review suggests feasibility and efficacy
of SBRT in the isolated lymph node cancer recurrence. Future
studies are urgently warranted to identify the patients that
benefit most from this treatment. The optimal combination
with systemic treatment should also be defined. The mecha-
nisms of SBRT interaction with cancer cells and the potential
effect of the drug-SBRT combination should also be investi-
gated.
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